Advancing Human Life. Together.
Read the full Annual Report 2024, which also contains our complete audited financial statement.
Strengthening future growth
Lachen, Switzerland
17/02/2025
Corporate news
Financial review 2024
“We remain strongly profitable, well-capitalised, and well-positioned for the future - with a focus on executing our long-term strategy while attracting and retaining talent by ensuring that Octapharma remains an employer of choice in the industry, expanding into new markets, and continuing operational improvements.”
Roger Mächler
Chief Financial Officer
The Octapharma Group continued to grow strongly in 2024, driven by increased demand across the portfolio - particularly in Critical Care, and operational improvements that continue to enhance efficiency and deliver economies of scale.
Sales rose 6.1% over the previous year to a new record high of €3.466 billion. Operating income was also a record €532 million – up 21.9% compared to 2023. Despite the increase in sales and production volumes, the cost of sales remained unchanged at €2.333 billion due to continuous improvements in the plasma collection and plasma production operations.
As a result, gross profit for the year was €1.133 billion - significantly higher than in 2023 - and gross margin jumped to 32.7% from 28.6%. Pre-tax income was a record €534 million compared with €429 million in 2023, while net income stood at €441 million. Net cash from operating activities was €542 million, up from €260 million in 2023.
In numbers
€ bn
Sales
€ m
Operating income
Number of employees
Operating expenses for the year rose to €601 million - up from €497 million in 2023. This reflects our continued investment in research and development of €108 million. Alongside the €294 million in capital expenditures, we invested over €400 million in initiatives which will maximise the potential of our portfolio, pipeline, and organisation in order to drive future growth.
Our investments are delivering efficiency gains across our organisation and that - combined with robust inventories of raw plasma - gives us confidence that we will deliver another strong set of results in 2025.
We remain strongly profitable, well-capitalised, and well-positioned for the future - with a focus on executing our long-term strategy while attracting and retaining talent by ensuring that Octapharma remains an employer of choice in the industry, expanding into new markets, and continuing operational improvements.
As always, none of this incredible success would have been possible without the commitment and support of our teams around the world. Together, we are on track to continue growing our company and helping even more patients in need around the world.
Roger Mächler
Chief Financial Officer
Keywords
Annual report